Our findings and functional assays on FOXA1 and ZBED2 demonstrate that the enhancer set and TF networks identified herein represent prime targets for further pre-clinical investigation for bladder cancer treatment. This evidence concerns the gene FOXA1 and urinary bladder carcinoma.